% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ewers:138230,
      author       = {Ewers, Michael and Mattsson, Niklas and Minthon, Lennart
                      and Molinuevo, José L and Antonell, Anna and Popp, Julius
                      and Jessen, Frank and Herukka, Sanna-Kaisa and Soininen,
                      Hilka and Maetzler, Walter and Leyhe, Thomas and Bürger,
                      Katharina and Taniguchi, Miyako and Urakami, Katsuya and
                      Lista, Simone and Dubois, Bruno and Blennow, Kaj and Hampel,
                      Harald},
      title        = {{CSF} biomarkers for the differential diagnosis of
                      {A}lzheimer's disease: {A} large-scale international
                      multicenter study.},
      journal      = {Alzheimer's and dementia},
      volume       = {11},
      number       = {11},
      issn         = {1552-5260},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DZNE-2020-04552},
      pages        = {1306-1315},
      year         = {2015},
      abstract     = {The aim of this study was to test the diagnostic value of
                      cerebrospinal fluid (CSF) beta-amyloid (Aβ1-42),
                      phosphorylated tau, and total tau (tau) to discriminate
                      Alzheimer's disease (AD) dementia from other forms of
                      dementia.A total of 675 CSF samples collected at eight
                      memory clinics were obtained from healthy controls, AD
                      dementia, subjective memory impairment, mild cognitive
                      impairment, vascular dementia, Lewy body dementia (LBD),
                      fronto-temporal dementia (FTD), depression, or other
                      neurological diseases.CSF Aβ1-42 showed the best diagnostic
                      accuracy among the CSF biomarkers. At a sensitivity of
                      $85\%,$ the specificity to differentiate AD dementia against
                      other diagnoses ranged from $42\%$ (for LBD, $95\%$
                      confidence interval or CI = 32-62) to $77\%$ (for FTD,
                      $95\%$ CI = 62-90).CSF Aβ1-42 discriminates AD dementia
                      from FTD, but shows significant overlap with other non-AD
                      forms of dementia, possibly reflecting the underlying mixed
                      pathologies.},
      keywords     = {Aged / Aged, 80 and over / Alzheimer Disease: cerebrospinal
                      fluid / Alzheimer Disease: diagnosis / Amyloid
                      beta-Peptides: cerebrospinal fluid / Biomarkers:
                      cerebrospinal fluid / Diagnosis, Differential / Female /
                      Humans / Internationality / Male / Middle Aged / Peptide
                      Fragments: cerebrospinal fluid / Phosphorylation /
                      Sensitivity and Specificity / Spinal Puncture / tau
                      Proteins: cerebrospinal fluid / Amyloid beta-Peptides (NLM
                      Chemicals) / Biomarkers (NLM Chemicals) / MAPT protein,
                      human (NLM Chemicals) / Peptide Fragments (NLM Chemicals) /
                      amyloid beta-protein (1-42) (NLM Chemicals) / tau Proteins
                      (NLM Chemicals)},
      cin          = {AG Maetzler},
      ddc          = {610},
      cid          = {I:(DE-2719)5000024},
      pnm          = {344 - Clinical and Health Care Research (POF3-344)},
      pid          = {G:(DE-HGF)POF3-344},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25804998},
      doi          = {10.1016/j.jalz.2014.12.006},
      url          = {https://pub.dzne.de/record/138230},
}